{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T10:32:56Z","timestamp":1782642776295,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bmcl.2021.128309","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T11:34:40Z","timestamp":1628249680000},"page":"128309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Privileged scaffolds in medicinal chemistry: Studies on pyrazolo[1,5-a]pyrimidines on sulfonamide containing Carbonic Anhydrase inhibitors"],"prefix":"10.1016","volume":"49","author":[{"given":"Arzu","family":"Gumus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Bozdag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Peat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Selleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bmcl.2021.128309_b0005","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1039\/C7MD00193B","article-title":"Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5- a]pyrimidines as potential anticancer agents","volume":"8","author":"Chandrakant","year":"2017","journal-title":"Med Chem Comm"},{"issue":"24","key":"10.1016\/j.bmcl.2021.128309_b0010","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1021\/jm100732t","article-title":"A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration","volume":"53","author":"Dean","year":"2010","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.bmcl.2021.128309_b0015","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1016\/j.bmcl.2007.09.017","article-title":"Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2","volume":"17","author":"Paruch","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.bmcl.2021.128309_b0020","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/cbdd.12618","article-title":"Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro","volume":"86","author":"\u0158ezn\u00ed\u010dkov\u00e1","year":"2015","journal-title":"Chem Biol Drug Des"},{"issue":"22","key":"10.1016\/j.bmcl.2021.128309_b0025","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1016\/j.bmcl.2009.09.087","article-title":"Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase","volume":"19","author":"Popovici-Muller","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.128309_b0030","article-title":"Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors","volume":"8","author":"Shen","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128309_b0035","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020859s011lbl.pdf (last access 17\/05\/2021)."},{"key":"10.1016\/j.bmcl.2021.128309_b0040","first-page":"765","article-title":"Indiplon in the treatment of sleep disorders","volume":"6","author":"Lankford","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"10.1016\/j.bmcl.2021.128309_b0045","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1517\/13543784.14.10.1269","article-title":"Indiplon: the development of a new hypnotic","volume":"14","author":"Neubauer","year":"2005","journal-title":"Expert Opin Invest Drugs"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128309_b0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/13543784.2015.987340","article-title":"Current Phase II investigational therapies for insomnia","volume":"24","author":"Zisapel","year":"2015","journal-title":"Expert Opin Invest Drugs"},{"issue":"20","key":"10.1016\/j.bmcl.2021.128309_b0055","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2021.128309_b0060","series-title":"Ullmann's Encyclopedia of Industrial Chemistry","author":"M\u00fcller","year":"2010"},{"issue":"9","key":"10.1016\/j.bmcl.2021.128309_b0065","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128309_b0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.bmcl.2021.128309_b0075","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128309_b0080","first-page":"309","article-title":"TRK inhibitors in TRK fusion-positive cancers","volume":"32","author":"Drilon","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128309_b0085","doi-asserted-by":"crossref","first-page":"18489","DOI":"10.1038\/s41598-020-75578-5","article-title":"Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2\/5\/9","volume":"10","author":"Saqub","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.bmcl.2021.128309_b0090","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2967\/jnumed.107.046151","article-title":"DPA-714, a New Translocator Protein-Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization","volume":"49","author":"James","year":"2008","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.bmcl.2021.128309_b0095","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1039\/C6MD00243A","article-title":"Design and synthesis of DNA-encoded libraries based on a benzodiazepine and a pyrazolopyrimidine scaffold","volume":"7","author":"\u0160kopi\u0107","year":"2016","journal-title":"Med. Chem. Commun."},{"issue":"21","key":"10.1016\/j.bmcl.2021.128309_b0100","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1021\/jm058002n","article-title":"A novel selective GABA(A) alpha1 receptor agonist displaying sedative and anxiolytic-like properties in rodents","volume":"48","author":"Selleri","year":"2005","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2021.128309_b0105","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.bmc.2017.02.013","article-title":"Synthesis and pharmacological evaluation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as potential GABAA-R ligands","volume":"25","author":"Guerrini","year":"2017","journal-title":"Bioorg Med Chem"},{"issue":"93","key":"10.1016\/j.bmcl.2021.128309_b0110","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejmech.2015.02.004","article-title":"Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO)","volume":"26","author":"Banister","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2021.128309_b0115","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0223-5234(92)90033-W","article-title":"Synthesis and preliminary evaluation of pyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-6(7H)-ones and related compounds, as benzodiazepine receptor ligands and anticonvulsant agents","volume":"27","author":"Selleri","year":"1992","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2021.128309_b0120","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.bmc.2018.04.011","article-title":"A new class of pyrazolo[5,1-c][1,2,4]triazines as \u03b3-aminobutyric type A (GABA A) receptor subtype ligand: synthesis and pharmacological evaluation","volume":"26","author":"Guerrini","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2021.128309_b0125","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase","volume":"246","author":"Khalifah","year":"1971","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128309_b0130","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem Rev"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21005369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21005369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:42:42Z","timestamp":1760773362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21005369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":26,"alternative-id":["S0960894X21005369"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128309","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Privileged scaffolds in medicinal chemistry: Studies on pyrazolo[1,5-a]pyrimidines on sulfonamide containing Carbonic Anhydrase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128309"}}